ID   N_N20R1
AC   CVCL_HG08
SY   N_N20R
DR   ECACC; 17011212
DR   Wikidata; Q54907287
DR   Ximbio; 152840
RX   PubMed=27323823;
CC   Selected for resistance to: ChEBI; CHEBI:46742; Nutlin-3.
CC   Derived from metastatic site: Lung.
ST   Source(s): ECACC
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 8,12
ST   D16S539: 8,11
ST   D18S51: 15,16
ST   D21S11: 32,33.1
ST   D3S1358: 17
ST   D5S818: 11,12
ST   D7S820: 11
ST   D8S1179: 11,12
ST   FGA: 19,23
ST   Penta D: 8,10
ST   Penta E: 11,15
ST   TH01: 9,9.3
ST   TPOX: 6,9
ST   vWA: 16,21
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_2141 ! NGP
SX   Male
AG   2Y6M
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 12-03-20; Version: 5
//
RX   PubMed=27323823; DOI=10.18632/oncotarget.10073;
RA   Drummond C.J., Esfandiari A., Liu J.-F., Lu X.-H., Hutton C.,
RA   Jackson J., Bennaceur K., Xu Q., Makimanejavali A.R., Del Bello F.,
RA   Piergentili A., Newell D.R., Hardcastle I.R., Griffin R.J., Lunec J.;
RT   "TP53 mutant MDM2-amplified cell lines selected for resistance to
RT   MDM2-p53 binding antagonists retain sensitivity to ionizing
RT   radiation.";
RL   Oncotarget 7:46203-46218(2016).
//